- Home
- AXGN
AXGN
Axogen Inc.
as 04-25-2025 4:00pm EST
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ALACHUA |
| Market Cap: | 887.3M | IPO Year: | N/A |
| Target Price: | $24.17 | AVG Volume (30 days): | 456.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.55 - $21.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $187,338,000 | Revenue Growth: | 17.81% |
| Revenue Growth (this year): | 18.1% | Revenue Growth (next year): | 16.29% |
Stock Insider Trading Activity of Axogen Inc. (AXGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '25 | Sell | $17.50 | 15,111 | $264,442.50 | 217,762 | |
| Wendell Amy McBride | AXGN | Director | Mar 3 '25 | Sell | $20.02 | 5,000 | $100,100.00 | 97,899 |
Latest Axogen Inc. News
AXGN Breaking Stock News: Dive into AXGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
Investor's Business Daily
a month ago
Stryker Stock Gets Relative Strength Rating Lift
GlobeNewswire
a month ago
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Axogen, Inc. (NASDAQ:AXGN) is a favorite amongst institutional investors who own 75%
MT Newswires
a month ago
Lake Street Initiates Axogen at Buy With $30 Price Target
Investor's Business Daily
2 months ago
Alcon Stock Gets Relative Strength Rating Lift
GuruFocus.com
2 months ago
Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ...
Thomson Reuters StreetEvents
2 months ago
Q4 2024 AxoGen Inc Earnings Call
Compare AXGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXGN Axogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.